Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Novartis AG — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $77, while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| JPIN | NVS | |
|---|---|---|
52-Week High | $77.00 | $168.62 |
52-Week Low | $64.96 | $119.31 |
Market Cap | — | $295.37B |
Sector | — | Health |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN (JPMorgan Diversified Return International Equity ETF) trades at $76.97, up 0.8% with strong technical momentum as moving averages signal bullish conditions. The ETF provides broad exposure to foreign large-cap value stocks through a smart beta approach. Recent dividend activity shows a $0.91 distribution scheduled for June 2026, while technical indicators show mixed signals with RSI in overbought territory but ADX confirming strong trend strength.
The ETF's outlook remains positive given its diversified international exposure and value orientation, though investors face currency risk and emerging market volatility. Current technical strength suggests continued upward momentum, but overbought RSI levels indicate potential near-term consolidation. The fund's systematic approach to international value investing provides defensive characteristics in volatile markets.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
